课题基金 / 基金详情

Core A - Administrative Core

Core A - Administrative Core
核心 A - 行政核心
批准号:
10006194
负责人:
Steven Mark Albelda
金额:
$12.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-14 至 2023-08-31

项目摘要

项目成果

Steven Mark Albelda的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Core A. Administrative Abstract The goals of the Administrative core will be: 1) coordinate effective interactions among projects, cores, oversight committees, and NCI staff, 2) provide Data safety and Monitoring support, ensuring that clinical trials are under the highest standards of “Good Clinical Practices” and that they comply with all the regulations of the University and other outside agencies, 3) support interactions with the Cancer Center and the Center for Cellular Immunotherapies, 4) support interactions with Industry, and 5) provide budget support, such as tracking the expenditures of the program and providing monthly reports to the investigators. This Core will also monitor Projects and other Cores and organize a yearly meeting with the External and Internal Advisory Boards. Given these broad integrative activities, the Core will interact closely with each Project and with the other two Cores in providing administrative, financial, and coordinating activities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2 - Preclinical studies: Overcoming tumor heterogeneity
  • 批准号:
    10006192
  • 项目类别:
  • 资助金额:
    $51.54万
  • 财政年份:
    2018
  • 负责人:
    Steven Mark Albelda
  • 依托单位:
Project 2 - Preclinical studies: Overcoming tumor heterogeneity
  • 批准号:
    10241978
  • 项目类别:
  • 资助金额:
    $51.54万
  • 财政年份:
    2018
  • 负责人:
    Steven Mark Albelda
  • 依托单位:
Core A - Administrative Core
  • 批准号:
    10241980
  • 项目类别:
  • 资助金额:
    $12.94万
  • 财政年份:
    2018
  • 负责人:
    Steven Mark Albelda
  • 依托单位:
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
  • 批准号:
    10006051
  • 项目类别:
  • 资助金额:
    $210.15万
  • 财政年份:
    2018
  • 负责人:
    Steven Mark Albelda
  • 依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究